Evommune vs Zenas BioPharma
EVMN and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVMN and ZBIO compare
Zenas BioPharma is the larger company, worth 6.6 times as much as Evommune ($1.8B against $277M).
Evommune scores higher on the StockData Score (7 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVMN | ZBIO |
|---|---|---|
| Size and price | ||
| Market cap | $277M | $1.8B |
| Share price | $7.63 | $28.01 |
| Change, 1 year | −60.9% | −21.8% |
| Beta (5Y) | 0.79 | 0.39 |
| Employees | 48 | 167 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.1× (better) | 8.6× |
| FCF yield | −32.9% | −13.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −100% | – |
| Profitability | ||
| Return on equity | −331% | −265% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 1.05 (better) |
| Current ratio | 8.52 | 9.42 (better) |
| Altman Z-score | 3.85 (better) | −1.46 |
| Piotroski F-score | 5 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 95.4% | 94.0% |
| Held by insiders | 51.6% | 36.1% |
| Insider net buying, 12 months | −$2.1M | $11.4M (better) |
| Short interest, % of float | 19.3% | 27.3% |
Go deeper
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
- ZBIO stock overview
- ZBIO income statement
- ZBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.